Drug
Buprenorphine Hydrochloride Marketed Sublingual
Buprenorphine Hydrochloride Marketed Sublingual: highest development phase Phase 2, developed by Indivior. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Indivior
Trials
| Drug | Phase | Indication |
|---|---|---|
| Buprenorphine hydrochloride marketed sublingual tablet (Subutex) NCT01075971 | Phase 2 | Opioid Dependency |
Latest
No recent events.
Follow Buprenorphine Hydrochloride Marketed Sublingual on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.